Last reviewed · How we verify
Tinidazole 500mg
At a glance
| Generic name | Tinidazole 500mg |
|---|---|
| Also known as | Global Pharma, Chennai, India |
| Sponsor | Kirby Institute |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- "Sexual Health Assessment of TinidaZole Against M. Genitalium (SHAZAM)" (PHASE2)
- Eradication of H. Pylori Infection With Moxifloxacin (PHASE3)
- Helicobacter Pylori First-line Treatment in Patients Allergic to Penicillin (PHASE4)
- Helicobacter Pylori Rescue Treatment Containing Tetracycline in Patients Allergic to Penicillin (PHASE4)
- LOAD VS Levofloxacine Concomitant (PHASE4)
- Comparing Efficacy of 14-day Therapy Doxycycline With Bismuth Subsalicylate Versus Levofloxacin With Tinadizole on Treatment Helicobacter Pylori (PHASE4)
- Efficacies of Antimicrobial Susceptibility-Guided Versus Empirical Therapy for Rescue Treatment of Helicobacter Pylori Infection (PHASE4)
- Antimicrobial Susceptibility Testing Guided Therapy Versus Empirical Therapy for the Rescue Treatment of Helicobacter Pylori Infection (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tinidazole 500mg CI brief — competitive landscape report
- Tinidazole 500mg updates RSS · CI watch RSS
- Kirby Institute portfolio CI